ArticleOncogene2002
The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- Two-way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3.FEBS open bio · 2025Article
- E proteins orchestrate dynamic transcriptional cascades implicated in the suppression of the differentiation of group 2 innate lymphoid cells.The Journal of biological chemistry · 2020Article
- Role of HDACs in normal and malignant hematopoiesis.Molecular cancer · 2020Review
- Emerging Roles of MTG16 in Cell-Fate Control of Hematopoietic Stem Cells and Cancer.Stem cells international · 2017Review
- miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.Molecular cancer · 2015Article
- Myeloid translocation gene-16 co-repressor promotes degradation of hypoxia-inducible factor 1.PloS one · 2015Article
- Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.Neoplasia (New York, N.Y.) · 2010Article
- Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis.Journal of cellular and molecular medicine · 2010Article
- Eto2/MTG16 and MTGR1 are heteromeric corepressors of the TAL1/SCL transcription factor in murine erythroid progenitors.Biochemical and biophysical research communications · 2009Article
- Novel RNA-binding properties of the MTG chromatin regulatory proteins.BMC molecular biology · 2008Article
- The human SIN3B corepressor forms a nucleolar complex with leukemia-associated ETO homologues.BMC molecular biology · 2008Article
- HDAC3: taking the SMRT-N-CoRrect road to repression.Oncogene · 2007Review
- A distinct epigenetic signature at targets of a leukemia protein.BMC genomics · 2007Article
- Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation.Oncogene · 2005Article
- Runx1/AML1 in normal and abnormal hematopoiesis.International journal of hematology · 2005Review
- Aberrant CBFA2T3B gene promoter methylation in breast tumors.Molecular cancer · 2004Article
- Bioinformatic analysis of the nucleolus.The Biochemical journal · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MTG (Myeloid Translocation Gene) proteins are a family of novel transcriptional corepressors. We report that MTG16a, a protein isoform encoded by the MTG16 gene deranged by the t (16; 21) in myeloid malignancies, is targeted to the nucleolus. The amino acid sequence necessary for nucleolar localization was mapped to the MTG16a N-terminal region. MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (HDACs) suggesting that the protein may mediate silencing of nucleolar gene transcription. In addition, MTG16a is capable to form oligomers with other MTG proteins. As a consequence of the t (16; 21) the AML1 DNA-binding domain replaces the MTG16a N-terminal region. The AML1-MTG16 fusion protein is targeted to the nucleoplasm where it is capable to oligomerize with MTG16a and interact with HDAC1 and HDAC3. The deficiency of HDAC-containing complexes at nucleolar sites and the accumulation of HDAC-containing complexes at AML1-sites may be critical in the pathogenesis of t (16; 21) myeloid malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.